Neumora Therapeutics reported a fourth‑quarter net loss of $59.4 million, a slight increase from the $58.8 million loss in Q4 2024, while the full‑year 2025 loss narrowed to $236.9 million from $243.8 million a year earlier. The company’s earnings per share of –$0.35 beat the consensus estimate of –$0.47, a $0.12 or 25.5% surprise, largely driven by disciplined cost management that offset the continued investment in its pipeline. Cash, cash equivalents and marketable securities stood at $182.5 million as of December 31 2025, giving the company a runway that management expects to extend through the third quarter of 2027.
R&D spending fell to $44.7 million in Q4 2025 from $45.9 million in Q4 2024, and the full‑year R&D expense dropped to $176.1 million from $200.9 million a year earlier, reflecting a reduction in navacaprant program costs and lower personnel expenses. General‑and‑administrative costs also declined, with full‑year G&A at $60.1 million versus $62.5 million in 2024, underscoring the company’s focus on operating leverage while maintaining a robust pipeline.
The company’s clinical pipeline advanced on multiple fronts. KOASTAL‑2 and KOASTAL‑3 navacaprant studies were fully enrolled in the first quarter of 2026, with a joint topline expected in the second quarter. New data from the NMRA‑511 Alzheimer’s agitation study were highlighted, and NMRA‑898 was named the lead program in the M4 positive allosteric modulator franchise. However, the 13‑week rat toxicology study for the obesity program NMRA‑215 revealed signals that delayed the clinical start to the first quarter of 2027, a setback that investors noted.
Management emphasized the progress made in 2025 and the foundation it has laid for future growth. “We saw significant progress in 2025, laying the foundation for a catalyst‑rich year ahead as we advance our pipeline of next‑generation therapies for people living with brain diseases,” said CEO Paul L. Berns. CFO Michael Milligan added, “As of December 31, 2025, we ended the year with $182.5 million in cash, cash equivalents and marketable securities. We expect our current cash position to support operations into the third quarter of 2027.”
Investors reacted negatively, citing the delay in the NMRA‑215 program as a key concern. The postponement of the clinical start to Q1 2027 dampened enthusiasm for the obesity asset, offsetting the positive momentum from the Alzheimer’s and depression pipeline updates. Despite the earnings beat, the market’s focus on the headwind from the toxicology findings tempered the overall reception.
Looking ahead, Neumora maintains confidence in its cash runway and the trajectory of its pipeline. The company expects the upcoming KOASTAL topline in Q2 2026 to provide a critical data point, while the NMRA‑511 and NMRA‑898 programs continue to progress toward regulatory milestones. The delayed NMRA‑215 start will be closely monitored, but the company’s strong financial position and disciplined cost structure position it to navigate the setback while pursuing its long‑term therapeutic goals.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.